344 related articles for article (PubMed ID: 18537193)
41. Mutations within protein kinase R-binding domain of NS5A protein of hepatitis C virus (HCV) and specificity of HCV antibodies in pretreatment sera of HCV-chronically infected patients and their effect on the result of treatment.
Kmieciak D; Kruszyna Ł; Migdalski P; Łaciński M; Juszczyk J; Trzeciak WH
Jpn J Infect Dis; 2006 Apr; 59(2):92-9. PubMed ID: 16632908
[TBL] [Abstract][Full Text] [Related]
42. Low-dose pegylated interferon-α2a plus ribavirin therapy for elderly and/or cirrhotic patients with HCV genotype-1b and high viral load.
Tamai H; Mori Y; Shingaki N; Kawashima A; Tsukuda H; Higashi K; Moribata K; Kawaguchi M; Ueda K; Deguchi H; Inoue I; Maekita T; Iguchi M; Kato J; Ichinose M
Antivir Ther; 2014; 19(1):107-15. PubMed ID: 24162072
[TBL] [Abstract][Full Text] [Related]
43. Effect of Hepatitis C Virus Genotype 1b Core and NS5A Mutations on Response to Peginterferon Plus Ribavirin Combination Therapy.
Nakamoto S; Imazeki F; Arai M; Yasui S; Nakamura M; Haga Y; Sasaki R; Kanda T; Shirasawa H; Yokosuka O
Int J Mol Sci; 2015 Sep; 16(9):21177-90. PubMed ID: 26370958
[TBL] [Abstract][Full Text] [Related]
44. Usefulness of a new immunoradiometric assay of HCV core antigen to predict virological response during PEG-IFN/RBV combination therapy for chronic hepatitis with high viral load of serum HCV RNA genotype 1b.
Sasase N; Kim SR; Kim KI; Taniguchi M; Imoto S; Mita K; Hotta H; Shouji I; El-Shamy A; Kawada N; Kudo M; Hayashi Y
Intervirology; 2008; 51 Suppl 1():70-5. PubMed ID: 18544951
[TBL] [Abstract][Full Text] [Related]
45. Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
Gonçales FL; Moma CA; Vigani AG; Angerami AF; Gonçales ES; Tozzo R; Pavan MH; Gonçales NS
BMC Infect Dis; 2010 Jul; 10():212. PubMed ID: 20646277
[TBL] [Abstract][Full Text] [Related]
46. Quasispecies of hepatitis C virus genotype 1 and treatment outcome with peginterferon and ribavirin.
Jardim AC; Yamasaki LH; de Queiróz AT; Bittar C; Pinho JR; Carareto CM; Rahal P; Mello IM
Infect Genet Evol; 2009 Jul; 9(4):689-98. PubMed ID: 19063998
[TBL] [Abstract][Full Text] [Related]
47. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
48. Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin.
Murakami E; Imamura M; Hayes CN; Abe H; Hiraga N; Honda Y; Ono A; Kosaka K; Kawaoka T; Tsuge M; Aikata H; Takahashi S; Miki D; Ochi H; Matsui H; Kanai A; Inaba T; McPhee F; Chayama K
Antimicrob Agents Chemother; 2014; 58(4):2105-12. PubMed ID: 24468783
[TBL] [Abstract][Full Text] [Related]
49. Mutations in hepatitis C virus genotype 1b and the sensitivity of interferon-ribavirin therapy after liver transplantation.
Fukuhara T; Taketomi A; Okano S; Ikegami T; Soejima Y; Shirabe K; Maehara Y
J Hepatol; 2010 May; 52(5):672-80. PubMed ID: 20346532
[TBL] [Abstract][Full Text] [Related]
50. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.
Fukuhara T; Taketomi A; Motomura T; Okano S; Ninomiya A; Abe T; Uchiyama H; Soejima Y; Shirabe K; Matsuura Y; Maehara Y
Gastroenterology; 2010 Nov; 139(5):1577-85, 1585.e1-3. PubMed ID: 20708617
[TBL] [Abstract][Full Text] [Related]
51. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G
J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817
[TBL] [Abstract][Full Text] [Related]
52. Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin.
Sede M; Laufer N; Ojeda D; Gun A; Cahn P; Quarleri J
Arch Virol; 2013 Sep; 158(9):1907-15. PubMed ID: 23553458
[TBL] [Abstract][Full Text] [Related]
53. Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin.
Yang SS; Lai MY; Chen DS; Chen GH; Kao JH
Liver Int; 2003 Dec; 23(6):426-33. PubMed ID: 14986817
[TBL] [Abstract][Full Text] [Related]
54. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors.
Shirakawa H; Matsumoto A; Joshita S; Komatsu M; Tanaka N; Umemura T; Ichijo T; Yoshizawa K; Kiyosawa K; Tanaka E;
Hepatology; 2008 Dec; 48(6):1753-60. PubMed ID: 18925643
[TBL] [Abstract][Full Text] [Related]
55. Serum proteome predicts virological response in chronic hepatitis C genotype 1b patients treated with pegylated interferon plus ribavirin.
Yen YH; Wang JC; Hung CH; Lu SN; Wang JH; Hu TH; Kee KM; Hsiao CC; Lee CM
J Formos Med Assoc; 2015 Jul; 114(7):652-8. PubMed ID: 23810703
[TBL] [Abstract][Full Text] [Related]
56. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
Sato M; Maekawa S; Komatsu N; Tatsumi A; Miura M; Muraoka M; Suzuki Y; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Uetake T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
J Virol; 2015 Jun; 89(11):6105-16. PubMed ID: 25810555
[TBL] [Abstract][Full Text] [Related]
57. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis.
Kim SR; Imoto S; Mita K; Taniguchi M; Sasase N; Muramatsu A; Kudo M; Kitai S; El-Shamy A; Hotta H; Hayashi Y
Digestion; 2009; 79(1):36-9. PubMed ID: 19246919
[TBL] [Abstract][Full Text] [Related]
58. ISDR pattern and evolution in patients with chronic hepatitis C treated with standard or PEG-IFN plus ribavirin.
Cappiello G; Abbate I; Lo Iacono O; Longo R; Solmone M; Ferraro D; Antonucci G; Di Marco V; Di Stefano R; Craxi A; Ippolito G; Capobianchi MR
Antivir Ther; 2003 Apr; 8(2):105-10. PubMed ID: 12741622
[TBL] [Abstract][Full Text] [Related]
59. Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy*.
Yuan HJ; Jain M; Snow KK; Gale M; Lee WM;
J Viral Hepat; 2010 Mar; 17(3):208-16. PubMed ID: 19656286
[TBL] [Abstract][Full Text] [Related]
60. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
